Infectious Disease and Immunology: Global Burden, Coverage and Care Landscape

Summary

This report maps the global infectious disease and immunology landscape using the latest available WHO, WUENIC-based, peer-reviewed and Global Burden of Disease evidence. Tuberculosis remains a major burden, with an estimated 10.7 million people falling ill and about 1.23 million deaths in the latest period ¹. Incidence fell only 12 percent over the comparison window, far from the End TB Strategy milestone of a 50 percent reduction ¹². Immunization has largely plateaued: DTP3 coverage reached 85 percent and 13.5 million infants received no initial DTP dose ⁴⁵. Bacterial antimicrobial resistance was associated with an estimated 4.71 million deaths ⁹, and a forecast reference scenario projects 39.1 million cumulative attributable deaths ⁸. Market size, spending, workforce and reimbursement data were not available in the pack. The main risks are stalled coverage, rising resistance and access gaps. The outlook points to a stronger case for access, surveillance and infection management investment, but commercial conclusions cannot be drawn from the verified evidence.

Key findings

1. 1

   Tuberculosis incidence is falling far too slowly

   Net incidence fell 12 percent over the comparison window, versus 29 percent for deaths, and remains far from the 50 percent End TB Strategy milestone.

   Confidence: High
2. 2

   Immunization coverage has plateaued with persistent zero-dose children

   DTP3 coverage reached 85 percent, and 13.5 million infants did not receive an initial DTP dose. MCV1 coverage at or above 90 percent was reported in 96 countries, fewer than the 98 countries reported earlier.

   Confidence: High
3. 3

   Undernutrition is a material, estimated driver of TB

   Undernutrition is estimated to contribute to about 2.2 million incident TB cases annually, roughly one-fifth of the burden. This is a modelled estimate, not an observed count.

   Confidence: Medium
4. 4

   Antimicrobial resistance carries a large forecast burden that better care could reduce

   The reference scenario forecasts 39.1 million cumulative attributable deaths, while a better care scenario could avert 92.0 million through improved severe infection management and antibiotic access. These are model forecasts.

   Confidence: Medium
5. 5

   Commercial market data for this segment is missing

   No verified market size, spending, pricing, reimbursement, workforce or company revenue data was retrieved, so market conclusions remain qualitative.

   Confidence: Qualitative

1Industry definition and scope

This report covers the infectious disease and immunology segment of global healthcare and life sciences. It groups four areas: tuberculosis (TB), including TB linked with HIV and undernutrition; vaccine-preventable diseases delivered through immunization, measured by DTP, IPV, MCV and HPV coverage ⁴⁷; bacterial antimicrobial resistance (AMR) ⁹; and viral infectious diseases of poverty, which the Global Burden of Disease analysis lists as COVID-19, HIV/AIDS, acute hepatitis, dengue, rabies and Ebola ¹⁰.

The scope is global, with regional detail where the pack provides it, such as sub-Saharan Africa for AIDS burden ¹⁰ and the WHO African Region for polio vaccine completion ⁷. The reporting period is the latest available data in each source. Sources use different periods, so figures are not always directly comparable.

Terminology matters. Incidence refers to new cases. Mortality refers to deaths. AMR sources distinguish deaths associated with resistance from deaths attributable to it ⁹. Zero-dose children are those who did not receive a first DTP dose ⁵. Incidence estimates for 130 countries combine UHC Service Coverage Index values with notification data ², so they are model-based in part.

Scope was set from the topics present in the source pack rather than from an external market definition.

2Market size, structure and value chain

The pack does not contain a verified market size, spending total, pricing data or revenue figure for infectious disease diagnostics, antibiotics, vaccines or immunology services. No market size is estimated here. Readers should treat any commercial sizing from other sources as outside the verified evidence base of this report.

Disease burden is the best available proxy for demand. Tuberculosis caused an estimated 10.7 million illnesses in the latest period ¹. Among incident TB cases, 5.8 percent were among people living with HIV ². These figures indicate the scale of need, not the scale of spending.

The value chain can be described in general terms, but the pack does not quantify it. Research and development, manufacturing, procurement, national immunization programs, clinical providers and laboratories all appear in the evidence, yet no verified data links them to money flows. The Global Polio Eradication Initiative, an industry association, reports on routine coverage and eradication ⁷, and WHO sets global targets and tracks progress ⁶⁹. These are coordination and measurement roles rather than revenue-generating roles.

• Estimated TB illnesses 10.7million people Observed Global, Latest available data [1]

Burden figures are shown as demand indicators only. They are not translated into market value.

3Customers, demand and adoption

The main end-user groups in the evidence are infants and children who need routine vaccines, people with TB or TB risk factors, people with HIV, people with undernutrition, and patients who receive antibiotics for severe bacterial infection. The pack reports demand through coverage and burden indicators rather than through purchasing behavior.

Vaccine demand remains unmet. About 110 million infants received three DTP doses in the latest period ⁶, yet 13.5 million infants did not receive an initial DTP dose ⁴. First-dose HPV coverage in girls was 33 percent, and HPV vaccine was delivered through national programs in 162 countries ⁴. The gap between national program availability and actual uptake is a key demand signal.

Regional access varies. In the WHO African Region, completion of the IPV primary series climbed from 47 percent to 60 percent ⁷, which shows measurable progress but leaves a large gap. In lower-income countries, 88 percent of infants received a first DTP dose ⁷, compared with 85 percent DTP3 coverage globally ⁴. The pack does not provide verified purchasing criteria, patient satisfaction or changing clinical expectations, so these are not assessed.

Table values come from one WHO source to keep the indicator set consistent.

4Competitive landscape and key players

The pack contains no company annual report, filing or market share data for anti-infective, vaccine or immunology providers. Company-level competitor comparison is therefore not possible, and no ranking of suppliers is offered. Any commercial conclusion about concentration or competitive pressure would be unsupported.

The evidence instead names organization types. WHO publishes global burden, coverage and AMR reporting ¹⁴⁹. The Global Polio Eradication Initiative reports routine coverage and eradication progress as an industry association ⁷. Johns Hopkins Bloomberg School of Public Health, through its Institute for Vaccine Safety, publishes peer-reviewed analysis of coverage gaps ⁵. The Antimicrobial Resistance Collaborators (GRAM Project) publish peer-reviewed burden modeling ⁸. These bodies are evidence producers and coordinators, not commercial competitors.

Comparing business models fairly is limited by the evidence. Public national immunization programs, WHO-coordinated targets and academic research groups operate under different mandates. The pack does not show how private providers, community providers or commercial suppliers compare on quality, price or access, so these comparisons are flagged as a data gap rather than inferred.

Comparable examples were limited to non-commercial evidence producers and coordinators.

5Technology, operations and workforce

Established practice in the evidence is routine vaccination delivered through national programs, with coverage measured by DTP, IPV, MCV and HPV indicators ⁴⁵⁷. MCV1 coverage was at or above 90 percent in 96 countries, compared with 98 countries previously ⁵. Operational performance is therefore measured mainly through coverage and dose completion rather than through productivity or cost.

TB and AMR burden estimates depend on modeling. TB incidence estimates for 130 countries combine country-specific service coverage values with notification data ². AMR burden is estimated from model-based scenarios ⁸. These methods are established in the research literature, but their accuracy depends on data quality in each country.

Emerging or experimental approaches are not verified in the pack. The better care scenario for AMR, which depends on improved severe infection management and antibiotic access, is a forecast rather than an observed intervention result ⁸. Workforce capacity for infectious disease physicians, immunology specialists and laboratory staff was not retrieved. Digital health adoption in these services was also not retrieved, so no statement about technology uptake is made.

Workforce and digital health claims are excluded because the pack holds no verified data for them.

6Regulation, standards, risk and sustainability

The pack does not include national laws or regulator texts for any jurisdiction, so no binding national requirement is described. The global references are WHO-led strategies and declarations. The End TB Strategy sets a 50 percent incidence reduction milestone ². The World Health Assembly AMR report sets a declaration target to reduce deaths associated with bacterial AMR by 10 percent from a baseline ⁹. Based on the pack, these are policy targets and voluntary commitments rather than binding law. Their legal status in any country should be checked against national sources.

Immunization progress is also tracked against Immunization Agenda targets, and WHO describes the trajectory as troubling ⁶. Targets set by WHO guide reporting and advocacy, but the pack does not show how they are enforced.

Privacy and ethics: this report uses aggregate population figures only. No individual patient data appears. The material is general industry analysis and is not medical, legal, investment or engineering advice. Key operational risks include stalled coverage, rising resistance and reliance on modelled estimates for TB and AMR. Sustainability and environmental factors are not covered by the pack and are not assessed.

• Estimated AMR-associated deaths 4.71million deaths Observed Global, Latest available data [9]

Targets are reported as stated by WHO. No compliance data was retrieved.

7Challenges, opportunities and case examples

The main constraint is slow progress against TB. Net TB incidence fell 12 percent, and a peer-reviewed analysis describes a modest 1 percent decline in incidence over a recent period, with incidence still above earlier levels ¹³. Undernutrition is estimated to contribute to about 2.2 million incident TB cases annually ³, which points to nutrition as a cross-cutting factor.

The second constraint is immunization access. The 13.5 million zero-dose children reported by WHO and the Johns Hopkins analysis show that gaps persist even as coverage holds steady ⁵⁶. Global IPV1 coverage held at 86 percent, while completion of the IPV primary series rose from 70 percent to 74 percent ⁷.

Opportunities are visible in specific programs. HPV vaccine is delivered through national programs in 162 countries ⁴, and the WHO African Region completed IPV primary series more often, rising from 47 percent to 60 percent ⁷. Case example one: the Johns Hopkins IVAC analysis identifies coverage gaps as a barrier to vaccine access ⁵. Case example two: the Global Polio Eradication Initiative links routine coverage estimates to eradication outcomes ⁷. Case example three: WHO links TB progress to the End TB Strategy milestone ². These are public and academic examples, and the pack contains no commercial case study.

Case examples are drawn only from the pack and are not used to infer commercial performance.

8Outlook and strategic implications

Near term, the evidence points to continued slow progress. TB incidence is falling far more slowly than the End TB Strategy requires ¹², and immunization coverage has held steady rather than risen ⁵⁶. This is an interpretation of observed trends rather than a forecast from the pack.

Medium term, AMR outcomes depend heavily on care quality. The reference scenario projects 39.1 million cumulative attributable deaths, while the better care scenario could avert 92.0 million ⁸. These are model forecasts and depend on assumptions about treatment and access. They should be read as scenarios, not predictions.

Practical implications for stakeholders are limited by the pack. Public health planners may prioritize zero-dose children, HPV delivery and infection management, since these are where the evidence shows the largest gaps ⁴⁵⁸. Researchers and suppliers would need verified market, pricing and reimbursement data before drawing commercial conclusions. Such data is a priority gap for future work.

Forecasts are reported as modelled outputs, not verified outcomes.

9Conclusion

Infectious disease and immunology remain high-burden areas with slow progress against TB and persistent immunization gaps. The most defensible takeaways are that burden is large and falling too slowly, that zero-dose children and access gaps persist, and that the verified evidence does not support commercial market conclusions.

How this was built

Sources

1. 1

   TB disease burden (Global Tuberculosis Report)

   World Health Organization Official statistics

   who.int
2. 2

   1.1 TB incidence (Global Tuberculosis Report)

   World Health Organization Official statistics

   who.int
3. 3

   Global tuberculosis epidemic: burden, progress towards End TB Strategy targets and systemic challenges

   ScienceDirect series (peer-reviewed journal article) Peer-reviewed

   sciencedirect.com
4. 4

   Immunization coverage (fact sheet)

   World Health Organization Official statistics

   who.int
5. 5

   Latest Global Immunization Coverage Estimates Illustrate Gaps in Vaccine Access

   Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety/IVAC Peer-reviewed

   publichealth.jhu.edu
6. 6

   Immunization and vaccine-preventable communicable diseases (GHO theme)

   World Health Organization Official statistics

   who.int
7. 7

   Immunization coverage: latest data and polio eradication

   Global Polio Eradication Initiative Industry association

   polioeradication.org
8. 8

   The Lancet: Global burden of bacterial antimicrobial resistance with forecasts

   Antimicrobial Resistance Collaborators (GRAM Project), The Lancet Peer-reviewed

   thelancet.com
9. 9

   WHA78 Antimicrobial resistance: Report by the Director-General

   World Health Organization Official statistics

   apps.who.int
10. 10

    Global burden of viral infectious diseases of poverty based on Global Burden of Disease study

    Global Burden of Disease study, published in PubMed Central Peer-reviewed

    ncbi.nlm.nih.gov